Oxaliplatin

Generic Name
Oxaliplatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H14N2O4Pt
CAS Number
61825-94-3
Unique Ingredient Identifier
04ZR38536J
Background

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication

Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions
Advanced Colorectal Cancer, Stage III Colon Cancer
Associated Therapies
-

Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors

First Posted Date
2004-04-02
Last Posted Date
2011-08-03
Lead Sponsor
Mayo Clinic
Registration Number
NCT00005068
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Phase 1
Completed
Conditions
First Posted Date
2004-04-02
Last Posted Date
2011-04-26
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00005860
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

First Posted Date
2004-03-11
Last Posted Date
2013-02-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT00016978
Locations
🇺🇸

CentraCare Clinic, Saint Cloud, Minnesota, United States

🇺🇸

CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States

🇺🇸

Rapid City Regional Hospital, Rapid City, South Dakota, United States

and more 21 locations

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

First Posted Date
2004-03-10
Last Posted Date
2020-05-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3397
Registration Number
NCT00079274
Locations
🇺🇸

Franklin Square Hospital Center, Baltimore, Maryland, United States

🇺🇸

Hematology and Oncology Associates, Chicago, Illinois, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

and more 872 locations

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2
Conditions
First Posted Date
2004-03-08
Last Posted Date
2009-01-13
Lead Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Registration Number
NCT00006115
Locations
🇫🇷

Hopital Tenon, Paris, France

🇫🇷

Hopital Claude Gallien, Quincy Sous Senart, France

🇫🇷

Hopital Saint Antoine, Paris, France

and more 13 locations

Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer

Phase 2
Completed
Conditions
First Posted Date
2004-03-04
Last Posted Date
2013-01-31
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Registration Number
NCT00005035
Locations
🇺🇸

Lutheran General Cancer Care Center, Park Ridge, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

and more 8 locations

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase 3
Conditions
First Posted Date
2004-02-16
Last Posted Date
2014-01-06
Lead Sponsor
Sanofi
Registration Number
NCT00008281
Locations
🇺🇸

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States

🇺🇸

Medical Oncology Internal Medicine, Los Angeles, California, United States

and more 129 locations

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

First Posted Date
2004-02-12
Last Posted Date
2013-09-05
Lead Sponsor
University of Chicago
Target Recruit Count
20
Registration Number
NCT00004203
Locations
🇺🇸

Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States

🇨🇦

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

and more 11 locations

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

First Posted Date
2004-02-11
Last Posted Date
2018-05-16
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
238
Registration Number
NCT00077233
Locations
🇺🇸

Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States

🇺🇸

MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States

🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 74 locations

Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2
Completed
Conditions
First Posted Date
2004-02-02
Last Posted Date
2021-02-17
Lead Sponsor
UNICANCER
Registration Number
NCT00006050
Locations
🇫🇷

Institut J. Paoli and I. Calmettes, Marseille, France

🇫🇷

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France

🇫🇷

Institut Gustave Roussy, Villejuif, France

© Copyright 2024. All Rights Reserved by MedPath